Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
News & insights
Blog Post: 23 JULY 2021
In the latest UK medical technology (Medtech) patent decision Insulet v Roche Diabetes Care  EWHC 1933 (Pat), Ms Pat Treacy (sitting as a judge of the High Court) held that (i) Roche Diabetes…Read more
News: 22 JULY 2021
Allen & Overy today announced that Sapna W. Palla has joined the firm as a partner in its intellectual property litigation practice, based in New York. Sapna joins from Wiggin & Dana LLP, where she…Read more
News: 27 MAY 2021
Allen & Overy has advised Exscientia on its USD 1.2 billion multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb (BMS).Read more